Karaali, RidvanDinc, Harika O.Ozdemir, Yusuf E.Dalar, Zeynep G.Kurt, Ahmet F.Aktas, Ayse N.Sirekbasan, Serhat2025-01-272025-01-2720221433-6510https://doi.org/10.7754/Clin.Lab.2021.211230https://hdl.handle.net/20.500.12428/21828Background: COVID-19 causes clinical manifestations ranging from asymptomatic infection to multi-organ failure. It is reported that those with severe disease have higher anti-SARS-CoV-2 antibody titers compared to asymptomatic or mild cases. We evaluated the correlation of antibody responses with laboratory and clinical indicators in COVID-19 patients. Methods: Seventy-nine male and 66 female patients (mean age: 39) with at least one positive SARS-CoV-2 RTPCR test and SARS-CoV-2 IgG antibody result after acute infection were included. Results: Seventy-six (52%), 45 (31%), and 24 (17%) patients had mild, moderate, and severe clinical findings, respectively. Patients with high body mass index and advanced age had significantly more severe disease (p < 0.001). A significant correlation was found between the increase in lymphopenia, C-reactive protein, ferritin, D-dimer, and lactate dehydrogenase and the severity of clinical findings (p = 0.0001). SARS-CoV-2 IgG antibody test was positive in 128 (88.3%) patients. A significant correlation was found between disease severity and antibody levels in the comparison of all groups (p < 0.001). Conclusions: Long-term monitoring of immune responses will be required to determine the appropriate time for the administration of new vaccines.eninfo:eu-repo/semantics/closedAccessSARS-CoV-2RT-PCRserologypublic healthArticle6891887189310.7754/Clin.Lab.2021.211230Q4WOS:0008664776000012-s2.0-8513813783336125145Q3